The pharmaceutical industry continues to be a lot of money to Doctors and hospitals. Within three years, the sum of 141 million Swiss francs (2015) has increased to nearly 163 million (2017).
This is evident from the Figures of the industry Association scienceindustries, the AWP is not available. Pharmaceutical companies in 2015, money values of benefits to professionals and organisations in the health sector.
Therefore, flowed from 162.5 million Swiss francs in the year 2017, more than half (91 million) to associations, teaching hospitals and other organizations. Approximately 60 million went into the research and 12.5 million to Doctors and other health professionals.
The Newspapers “the observer”, “trade newspaper”, “Blick” and “Le Temps” had on Thursday, as first reported.
Novartis pays the most
the cafeteria was Novartis. The Basel pharmaceutical company has 19.9 million Swiss francs jump, the generics subsidiary, Sandoz, not counting. Behind Roche, with 13.9 million Swiss francs, and Bayer 12.0 million. Around 10 million Swiss francs, facing Bristol-Myers Squibb, Pfizer and AstraZeneca. With their transparency, offensive, wants to remove the pharmaceutical industry from your bad reputation of the past, as Doctors were lured with luxury travel. According to the “observer”, the more detailed data are available, increased the Rate of Doctors who give the consent to the publication of their names, to 73 percent.
Novartis completes since 2016 there is no cooperation contracts with Doctors who refuse to disclose your information, the “Handelszeitung”. Here, the ratio is at 100 percent. At Roche, the transparency ratio was at 80 percent.
Switzerland compared to the front
Germany, along with Austria compared with Switzerland is still some catching up to do in terms of transparency. In both countries, the disclosure rate is just 30 percent.
in this Country, the pressure on the sector increases by the associations. So, the industry Association Scienceindustries has publish starting in the summer of 2018, all companies that do not come in 2018 to a disclosure rate of 80 percent.
“Switzerland is in terms of transparency and disclosure of its neighbouring countries, but also countries such as the UK way ahead”, explains Jürg Gran Weir, head of Pharma at the Association of science industries, in conversation with AWP. “And we are pushing ahead with the disclosure.”
oncologist Association, the largest recipient
the question, to whom or what the funding Remains. The largest recipient of the European oncologists Association of ESMO with headquarters in Lugano, which received 10.3 million Swiss francs according to the analysis,. This also reflects the great importance of cancer research for the entire industry.
Under the Unispitalern the Inselspital Bern to fins with 2.7 million at the most. But the Zurich Unispital was one of 2.2 million of the larger receivers. The cooperation with the industry enables the hospitals to new developments. (sda/red)
Created: 11.04.2019, 12:41 PM
